Skip to content
memoinOncology Logo memoinOncology Logo memoinOncology Logo
  • CONGRESS REPORTS
    • Solid Tumors
      • ASCO
      • EANM
      • ESMO
      • ESMO IO
    • Hematology
      • ASH
      • EHA
      • ESH CLL
      • ISHL
      • iwWM
    • Lung Cancer
      • ASCO
      • CSCO
      • ECC
      • ELCC
      • ESMO
      • ESMO Asia
      • WCLC
  • MEDICAL EDUCATION
    • Clinical Trials
    • Preceptorship reports
    • Articles
  • COLLABORATIONS
    • CSCO
    • LACOG
    • SEO
    • SSO
  • SUPPORTER
    • Boehringer Ingelheim in Oncology
    • BeiGene
    • ITM
  • MORE…
    • ABOUT US
    • LINKS
    • CALENDAR
    • VIDEOS

Disease monitoring using circulating cell-free tumour DNA

Disease monitoring using circulating cell-free t

Read More

Treatment of lung cancer: status quo & news from ASCO 2016

Treatment of lung cancer: status quo & news

Read More

Staging of lung cancer: the 8th TNM classification

Staging of lung cancer: the 8th TNM classificati

Read More

Screening and early detection of lung cancer

Screening and early detection of lung cancer

Read More

Pathology and WHO classification of tumours of the lung: what is new?

Pathology and WHO classification of tumours of t

Read More

HER2 驱动突变抑制能够带来获

HER2 驱动突变抑制能够带来获 在 NSCLC   中已经 发现 HER2 (ErbB2)的扩增或超

Read More

改变实践的肺癌分期细分完善

改变实践的肺癌分期细分完善 第 8 版 TNM 分类已于近期开始实施。与 2009 年发布的第七版[1

Read More

采用尼达尼布(nintedanib)抗血管生成:在间皮瘤中的活性和潜在生物标志物

采用尼达尼布(nintedanib)抗血管生成:在间皮瘤中的活性和潜在生物标志物 LUME-Meso

Read More

哪类人群适合免疫疗法?

哪类人群适合免疫疗法? Johan Vansteenkiste, ,医学博士  比利时鲁汶大学校医院呼

Read More

免疫疗法:新型抗 PD-L1 抗体与各种组合方案

免疫疗法:新型抗 PD-L1 抗体与各种组合方案 OAK 亚组分析 与抗 PD-1 抗体相比,针对 P

Read More
12Next

Sponsors:
This website is intended only for healthcare professionals outside the US, the UK, and Australia   |   This website is supported by an unrestricted medical education grant from BeiGene, Boehringer Ingelheim and ITM
© Copyright 2012 -  memoinOncology BY SPRINGER-VERLAG GmbH   |   Projekt: infill healthcare communication GmbH.   |   Alle Rechte vorbehalten.   |   Die Nutzung der Inhalte ist ausschließlich für den privaten Gebrauch bestimmt. Die über den persönlichen Gebrauch hinausgehende Vervielfältigung und Verbreitung ist nicht gestattet.
Impressum   |   Datenschutzerklärung   |   AGB   |   Kontakt   |   Cookie Einstellungen

Accessibility by WAH